G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

PURPOSE: The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Andreano, Kaitlyn J., Wardell, Suzanne E., Baker, Jennifer G., Desautels, Taylor K., Baldi, Robert, Chao, Christina A., Heetderks, Kendall A., Bae, Yeeun, Xiong, Rui, Tonetti, Debra A., Gutgesell, Lauren M., Zhao, Jiong, Sorrentino, Jessica A., Thompson, Delita A., Bisi, John E., Strum, Jay C., Thatcher, Gregory R. J., Norris, John D.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Preclinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7103015/
https://ncbi.nlm.nih.gov/pubmed/32130619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05575-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados